Antipsychotic polypharmacy in high-utilising patients with schizophrenia;Antipsychotische Polypharmazie bei Patienten mit Schizophrenie und hoher Versorgungsinanspruchnahme

Psychiatrische Praxis

Volumn 40, Issue 7, 2013, Pages 380-384

  Schmidt Kraepelin, Christian ^a   Puschner, Bernd ^b   Loos, Sabine ^b   Janssen, Birgit ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

antipsychotic; combination treatment; high utilising patients; polypharmacy; schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CHRONIC PATIENT; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); POLYPHARMACY; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; THERAPY RESISTANCE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENCHMARKING; CLOZAPINE; COMORBIDITY; COST-BENEFIT ANALYSIS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; GERMANY; GUIDELINE ADHERENCE; HEALTH SERVICES MISUSE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEEDS ASSESSMENT; PATIENT DISCHARGE; PATIENT READMISSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885378192     PISSN: 03034259     EISSN: 14390876     Source Type: Journal    
DOI: 10.1055/s-0033-1343185     Document Type: Article

References (15)

1. Correll C. U., Rummel-Kluge C., Corves C. et al. Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. Schizophr Bull: 2009; 35 443 457
2. Stahl S. M., Grady M. M. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Current Medicinal Chemistry: 2004; 11 313 327 (Pubitemid 38240209)
3. Messer T., Schmauß M. Polypharmazie in der Behandlung psychischer Erkrankungen. Wien, New York Springer: 2006
4. Oepen G. Polypharmacy in Schizophrenia. In: Ghaemi N. S. eds. Polypharmacy in Psychiatry. 1st Edition. New York Marcel Dekker Inc: 2002; 101 132
5. Schroeder N. H., Caffey E. M., Lorei T. W. Antipsychotic drug use: Physician prescribing practices in relation to current recommendations. Dis Nerv Syst: 1977; 38 114 116 (Pubitemid 8042414)
6. Faries D., Ascher-Svanum H., Zhu B. et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry: 2005; 5 26
7. Freudenreich O., Goff D. C. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand: 2002; 106 323 330 (Pubitemid 35176874)
8. Tranulis C., Skalli L., Lalonde P. et al. Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Safety: 2008; 31 7 20
9. Citrome L., Jaffe A., Levine J. et al. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv: 2004; 55 1006 1013 (Pubitemid 39209683)
10. Joukamaa M., Heliövaara M., Knekt P. et al. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry: 2006; 188 122 127 (Pubitemid 43171066)
11. Puschner B., Steffen S., Gaebel W. et al. Needs-oriented discharge planning and monitoring for high utilisers of psychiatric services (NODPAM): design and methods. BMC Health Serv Res: 2008; 8 152
12. Endicott J., Spitzer R. L., Fleiss J. L. et al. The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance. Arch Gen Psychiatry: 1976; 33 766 771
13. Chisholm D., Knapp M. R., Knudsen H. C. et al. Client Socio-Demographic and Service Receipt Inventory-European Version: development of an instrument for international research. Br J Psychiatry: 2000; 39 01 28 33
14. Rittmannsberger H. The use of drug monotherapy in psychiatric inpatient treatment. Prog Neuropsychopharmacol Biol Psychiatry: 2002; 26 547 551 (Pubitemid 34252949)
15. Muijen M, Silverstone T. A comparative hospital survey of psychotropic drug prescribing. Br J Psychiatry 1987; 150: 501-504 (Pubitemid 17057770)